Monday, 23 July 2018 - 6:48
  • it
  • de
  • en
  • fr

Advair

First results from GSK’s combo HIV therapy

ViiV, a subsidiary of  GlaxoSmithKline’s having also Pfizer and Shionogi as shareholders, has reported positive early results from the Phase III Gemini-1 and Gemini-2 clinical trials, enrolling 1,400 patients with HIV, treated with a dolutegravir-lamivudine combo therapy for 48 weeks….

GSK seeks to protect Advair through GBP1.2bn acquisition of Vectura

The British newspaper The Telegraph has reported today that the pharma giant GSK is about to offer GBP1.2bn for UK-based Vectura. The reported offer corresponds to GBP1.75 per share, that is a 53% premium over yesterday’s closing price. A takeover…

GSK celebrates non-approval of Hikma-developed generic Advair

GlaxoSmithKline scored another victory as FDA this week rejected to approve the generic of blockbuster Advair Diskus, developed by generic manufacturer Hikma. Britain-based Hikma Pharmaceuticals is seeking the same multibillion-pound sales that the asthma drug (fluticasone propionate and salmeterol) developed…